Versantis AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Versantis AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10992
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Versantis AG (Versantis) is a pharmaceutical company that develops new generation of medicines and diagnostics for treating patients with liver diseases. The company’s pipeline product includes VS-01, a liposomal-based peritoneal dialysis fluid that acts as a clearance enhancer for a large spectrum of toxic metabolites accumulated during liver and kidney failures. Its other pipeline products include VS-02 and VS-03 which are being developed for the treatment of drug intoxications and chronic liver diseases. Versantis also conducts preclinical development and late stage research for the treatment of metabolic acidemias and for the diagnosis of hyperammonemia. The company develops detoxification technology with the combination of pharmaceutical technology called liposomes and peritoneal dialysis. Versantis is headquartered in Zurich, Switzerland.

Versantis AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Versantis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versantis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versantis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versantis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versantis AG, Medical Devices Deals, 2012 to YTD 2018 9
Versantis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Versantis AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Versantis Pharma Raises USD4.4 Million in Series A Financing 11
Versantis Raises USD0.18 Million in Seed Financing 13
Equity Offering 14
Versantis Spin Out from ETH Zurich 14
Versantis AG – Key Competitors 15
Versantis AG – Key Employees 16
Versantis AG – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Versantis AG, Pharmaceuticals & Healthcare, Key Facts 2
Versantis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versantis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versantis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versantis AG, Deals By Therapy Area, 2012 to YTD 2018 8
Versantis AG, Medical Devices Deals, 2012 to YTD 2018 9
Versantis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Versantis Pharma Raises USD4.4 Million in Series A Financing 11
Versantis Raises USD0.18 Million in Seed Financing 13
Versantis Spin Out from ETH Zurich 14
Versantis AG, Key Competitors 15
Versantis AG, Key Employees 16

List of Figures
Versantis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Versantis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Versantis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Versantis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Versantis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versantis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Versantis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versantis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versantis AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Versantis AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野:企業M&A・提携分析
    Summary Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of novel drugs for the treatment of serious and life-threatening diseases. The company offers Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treat …
  • Swiss Post Ltd:企業の戦略的SWOT分析
    Swiss Post Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Aero Components Inc.:企業の戦略・SWOT・財務情報
    Aero Components Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Components Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • NicOx SA (COX):企業の財務・戦略的SWOT分析
    Summary NicOx SA (NicOx) is an ophthalmology company that develops solutions to help maintain vision and improve ocular health. The company’s products include Vyzulta, a latanoprostene bunod ophthalmic solution; and Zerviate, a cetirizine ophthalmic solution. It offers products in the therapeutic ar …
  • Decathlon S.A.:企業の戦略・SWOT・財務情報
    Decathlon S.A. - Strategy, SWOT and Corporate Finance Report Summary Decathlon S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • LM Wind Power Holding AS:企業の戦略的SWOT分析
    LM Wind Power Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • RedHill Biopharma Ltd (RDHL):製薬・医療:M&Aディール及び事業提携情報
    Summary RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes therapeutics in the areas of gastroenterology (GI) and cancer. The company’s commercial product portfolio consists of Donnatal for IBS and acute enterocolitis; Esomeprazole Strontium Delayed-Relea …
  • Limacorporate SpA:医療機器:M&Aディール及び事業提携情報
    Summary Limacorporate SpA (Lima) is a medical device company that develops, manufactures and commercializes reconstructive and fixation orthopaedic solutions. The company offers large joint primary and revision implants, extremities and fixation and promade products. It provides medical devices for …
  • Enterprise Holdings, Inc.:企業の戦略・SWOT・財務情報
    Enterprise Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Enterprise Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SilverSun Technologies Inc (SSNT):企業の財務・戦略的SWOT分析
    Summary SilverSun Technologies Inc (SilverSun) is a technology company that offers transformational business technology solutions and services for manufacturers and distributors. The company’s ERP software products comprise ERP X3, MAS90 and MAS200. It offers network services such as 24/7 remote net …
  • Nexgenia Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Nexgenia Inc (Nexgenia) is a developer and manufacturer of proprietary polymer-based reagents. The company offers stimuli-responsive polymers and polymer-containing magnetic nanoparticles that develops speed, efficiency and sensitivity of molecular and cell separations for diagnostic and lif …
  • High Peak Royalties Ltd (HPR):企業の財務・戦略的SWOT分析
    High Peak Royalties Ltd (HPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Pacific Edge Ltd (PEB):企業の財務・戦略的SWOT分析
    Summary Pacific Edge Ltd (PEB) is a diagnostics company that develops, discovers, and commercializes diagnostic tests for the early detection and monitoring of cancer. The company provides lead product such as Cxbladder, a non-invasive laboratory test for the detection of bladder cancer. It also dev …
  • Universal Electronics Inc (UEIC):企業の財務・戦略的SWOT分析
    Summary Universal Electronics Inc (Universal Electronics) is a technology company that offers control and sensor technology solutions. The company offers a range of pre-programmed and universal remote control products, audio-video accessories, intelligent wireless security and automation components, …
  • Zymeworks Inc:企業のM&A・事業提携・投資動向
    Zymeworks Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Zymeworks Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Dixons Carphone plc:企業のM&A・事業提携・投資動向
    Dixons Carphone plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dixons Carphone plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • NETGEAR Inc (NTGR):企業の財務・戦略的SWOT分析
    NETGEAR Inc (NTGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Arthur J. Gallagher & Co:企業の戦略・SWOT・財務情報
    Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report Summary Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆